Clinical Trial Search

Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299

Primary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants

Primary: Logarithm of Percentage of Baseline Ulcer Size — 3.6043; 3.5030 Mean of log (percentage of baseline area — p=0.652

Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days — 24; 104 SAEs and AEs

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml

Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants

Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale

Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale

Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: SCORAD Change Score — 33.34 Change Score

Primary: The Mean Subcutaneous Adipose Tissue Thickness Changes (mm) Between the Visit 3 and Baseline by Ultrasound Examination. — 2.5 mm

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants

Primary: Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator's Direct Observation. — 1; 4; 3…

Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale

Primary: Incidence of Incontinence-associated Dermatitis (IAD) — 18; 8; 5; 5 Participants

Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…

Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants

Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants

Primary: Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0) — 14.53; 16.03; 109.1; 110.7 pg/ml

Primary: Change From Baseline in Extent of Telangiectasias — 57.24; 76.08 percent of change negative values

Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change

Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001

Primary: Number of Partecipants With Improvement of Dermatitis Severity — 37 Participants